Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Payables (2016 - 2026)

Collegium Pharmaceutical has reported Payables over the past 11 years, most recently at $10.7 million for Q4 2025.

  • For Q4 2025, Payables rose 170.95% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, up 170.95%, while the annual FY2025 figure was $10.7 million, 170.95% up from the prior year.
  • Payables for Q4 2025 was $10.7 million at Collegium Pharmaceutical, up from $7.6 million in the prior quarter.
  • Over five years, Payables peaked at $17.9 million in Q1 2025 and troughed at $2.4 million in Q2 2024.
  • A 5-year average of $6.5 million and a median of $6.3 million in 2022 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 63.48% in 2023 and later surged 351.49% in 2025.
  • Year by year, Payables stood at $4.2 million in 2021, then fell by 16.59% to $3.5 million in 2022, then skyrocketed by 148.77% to $8.7 million in 2023, then plummeted by 54.74% to $3.9 million in 2024, then skyrocketed by 170.95% to $10.7 million in 2025.
  • Business Quant data shows Payables for COLL at $10.7 million in Q4 2025, $7.6 million in Q3 2025, and $10.9 million in Q2 2025.